Literature DB >> 23321266

Recruitment strategy cost and impact on minority accrual to a breast cancer prevention trial.

Alexander Dew1, Seema Khan, Christie Babinski, Nancy Michel, Marie Heffernan, Stefanie Stephan, Neil Jordan, Borko Jovanovic, Paula Carney, Raymond Bergan.   

Abstract

BACKGROUND: Recruitment of minorities to cancer prevention trials is difficult and costly. Early-phase cancer prevention trials have fewer resources to promote recruitment. Identifying cost-effective strategies that can replace or supplement traditional recruitment methods and improve minority accrual to small, early-phase cancer prevention trials are of critical importance.
PURPOSE: To compare the costs of accrual strategies used in a small breast cancer prevention trial and assess their impact on recruitment and minority accrual.
METHODS: A total of 1196 potential subjects with a known recruitment source contacted study coordinators about the SOY study, a breast cancer prevention trial. Recruitment strategies for this study included recruitment from within the Northwestern University network (internal strategy), advertisements placed on public transportation (Chicago Transit Authority (CTA)), health-related events, media (print/radio/television), and direct mail. Total recruitment strategy cost included the cost of study personnel and material costs calculated from itemized receipts. Incremental cost-effectiveness ratios (ICERs) were calculated to compare the relative cost-effectiveness of each recruitment strategy. If a strategy was more costly and less effective than its comparator, then that strategy was considered dominated. Scenarios that were not dominated were compared. The primary effectiveness measure was the number of consents. Separate ICERs were calculated using the number of minority consents as the effectiveness measure.
RESULTS: The total cost of SOY study recruitment was US$164,585, which included the cost of materials (US$26,133) and personnel (US$138,452). The internal referral strategy was the largest source of trial contacts (748/1196; 63%), consents (107/150; 71%), and minority consents (17/34; 50%) and was the most expensive strategy (US$139,033). CTA ads generated the second largest number of trial contacts (326/1196; 27%), the most minority contacts (184/321; 57%), and 16 minority consents (16/34; 47%), at a total cost of US$15,562. The other three strategies yielded many fewer contacts and consents. The methods of health events, CTA ads, and the internal strategy showed some evidence of cost-effectiveness (ICER: US$581, US$717, and US$1524, respectively). The CTA strategy was the most cost-effective strategy for minority accrual (ICER: US$908). LIMITATIONS: Recall bias may have limited the accuracy of estimated time spent on recruitment by study personnel. Also, costs spent specifically on minority accrual were unobtainable; results may not be generalizable to other settings; and cost-effectiveness data for the methods of media, health events, and direct mail should be interpreted with caution since these methods generated few consents.
CONCLUSIONS: Public transportation ads have the potential to generate numerous minority contacts and consents at a reasonable cost within an urban setting. Combined with traditional methods of recruitment, this method can lead to timelier study completion and increased minority accrual. Future research should prospectively track recruitment and costs in order to better assess the cost-effectiveness of recruitment methods used to target minority populations.

Entities:  

Mesh:

Year:  2013        PMID: 23321266     DOI: 10.1177/1740774512471452

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  7 in total

1.  African Americans' and Hispanics' information needs about cancer care.

Authors:  Teresita Muñoz-Antonia; Danielle Ung; F Alejandro Montiel-Ishino; Alison Nelson; Jorge Canales; Gwendolyn P Quinn
Journal:  J Cancer Educ       Date:  2015-06       Impact factor: 2.037

2.  The influence of health disparities on targeting cancer prevention efforts.

Authors:  Alan B Zonderman; Ngozi Ejiogu; Jennifer Norbeck; Michele K Evans
Journal:  Am J Prev Med       Date:  2014-03       Impact factor: 5.043

3.  Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema.

Authors:  Kathleen M Sturgeon; Renata Hackley; Anna Fornash; Lorraine T Dean; Monica Laudermilk; Justin C Brown; David B Sarwer; Angela M DeMichele; Andrea B Troxel; Kathryn H Schmitz
Journal:  Cancer       Date:  2017-09-07       Impact factor: 6.860

4.  Disparities in awareness of and willingness to participate in cancer clinical trials between African American and White cancer survivors.

Authors:  Gaurav Kumar; Jungyoon Kim; Paraskevi A Farazi; Hongmei Wang; Dejun Su
Journal:  BMC Cancer       Date:  2022-09-15       Impact factor: 4.638

5.  Using Social Media to Facilitate Communication About Women's Testing: Tool Validation Study.

Authors:  Tara Coffin; Deborah Bowen; Karen Lu; Elizabeth M Swisher; Nadine Rayes; Barbara Norquist; Stephanie V Blank; Douglas A Levine; Jamie Nadine Bakkum-Gamez; Gini F Fleming; Olufunmilayo I Olopade; Iris Romero; Alan D'Andrea; Denise R Nebgen; Christine Peterson; Mark F Munsell; Kathleen Gavin; Jamie Crase; Deborah Polinsky; Rebecca Lechner
Journal:  JMIR Form Res       Date:  2022-09-26

6.  Recruiting hard-to-reach pregnant women at high psychosocial risk: strategies and costs from a randomised controlled trial.

Authors:  Alice MacLachlan; Karen Crawford; Shona Shinwell; Catherine Nixon; Marion Henderson
Journal:  Trials       Date:  2021-06-16       Impact factor: 2.728

7.  Yields and costs of recruitment methods with participant phenotypic characteristics for a diabetes prevention research study in an underrepresented pediatric population.

Authors:  Kiley B Vander Wyst; Micah L Olson; Elva Hooker; Erica G Soltero; Yolando P Konopken; Colleen S Keller; Felipe G Castro; Allison N Williams; Arlene D R Fernández; Donald L Patrick; Stephanie L Ayers; Houchun H Hu; Armando Peña; Janiel Pimentel; William C Knowler; Gabriel Q Shaibi
Journal:  Trials       Date:  2020-08-14       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.